Is the time to progression ratio an appropriate endpoint for clinical trials? A critical examination of current practice and suggestions for a new methodology

Background: The time to progression ratio (TTPr) is a novel endpoint in Phase I/II oncology trials, which is frequently applied to evaluate the efficacy of molecular targeted treatments in late stage patients. The general idea of the design is that a patient serves as their own control. To[for full text, please go to the a.m. URL]
65th Annual Meeting of the German Association for Medical Informatics, Biometry and Epidemiology (GMDS), Meeting of the Central European Network (CEN: German Region, Austro-Swiss Region and Polish Region) of the International Biometric Society (IBS)